Takeda's killer product not as straightforward as it seems. ..
Costs Unsustainable for New Angioedema Preventive Therapies in US, Real-world Data Show
https://angioedemanews.com/2020/05/13/takhzyro-haegarda-prophylactics-costs-unsustainable-preventive-hae-attacks-us-real-world-data/
Also CSL isn't just a one-product company so am sure it can absorb any damage it faces.
The CSL pattern, page-262
-
- There are more pages in this discussion • 1,055 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$307.61 |
Change
-0.950(0.31%) |
Mkt cap ! $149.1B | |||
| Open | High | Low | Value | Volume |
| $307.48 | $307.80 | $306.25 | $17.44M | 56.75K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1 | $307.59 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $307.66 | 21 | 3 |
View Market Depth
| Last trade - 10.22am 16/07/2024 (20 minute delay) ? |
| CSL (ASX) Chart |